The race is on for new drugs that suppress appetite, improve glucose regulation and can replace injections. But do they ...

Data from Hengrui’s Phase II trial for its GLP-1/GIP product demonstrated a statistically significant mean weight loss of ...

Kentucky leads the nation with 21 prescriptions per 1,000 residents, reflecting its 36.5% obesity rate and robust healthcare access.

Adults with type 2 diabetes using a GLP-1 receptor agonist have a similar risk for developing thyroid cancer as those using a ...

We recently compiled a list of the 10 Best Diabetes Stocks To Buy Under $10. In this article, we are going to take a look at ...

We recently compiled a list of the 10 Best Diabetes Stocks To Buy Under $10. In this article, we are going to take a look at ...

My weight concerns mainly injure my considerable vanity, and I’m not about to outsource my self-esteem issue to Big Pharma if ...

On the one hand, its impressive business performance can make investors ponder potential life-changing investment returns. Conversely, feeling confident in Hims & Hers Health can sometimes be ...

Register for BNC#7 here. GLP-1 receptor agonists are revolutionizing health care, moving beyond diabetes and obesity to treat cardiovascular, kidney, and possibly neurodegenerative diseases. As usage ...

On the flip side, the success of GLP-1 receptor agonists is sparking renewed interest in general medicines, with companies ...

Liraglutide improves blood sugar levels by creating similar effects in the body as GLP-1 in the pancreas, which is often found in insufficient levels in those with type 2 diabetes. The prescribing ...